American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived

by admin April 3, 2025
April 3, 2025
European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived

Pharmaceutical stocks saw strong gains on Thursday after US President Donald Trump announced that pharmaceuticals would be exempt from the latest round of reciprocal tariffs on global imports.

The exemption has provided a much-needed boost to the sector, particularly for Indian and European drugmakers, which rely heavily on US sales.

However, analysts have cautioned that broader tariff risks still loom over the industry.

European pharma stocks climb, but uncertainty remains

Following Trump’s announcement, major pharmaceutical stocks across Europe and Asia posted gains.

In the UK, AstraZeneca and GlaxoSmithKline (GSK) both climbed about 1.5%, while Swiss drugmaker Novartis gained 0.69%.

France’s Sanofi also edged higher by 0.3%.

However, Swiss pharmaceutical giant Roche fell 2.3% after its multiple sclerosis drug Ocrevus failed to meet its primary endpoint in a key clinical trial.

While the immediate exemption of pharmaceuticals has been welcomed by the industry, analysts warn that uncertainties remain.

Shore Capital healthcare analyst Sean Conroy noted that a White House fact sheet indicated pharmaceuticals were excluded from the new tariff measures.

However, he added, “It is still somewhat unclear whether the broader-reaching 10% baseline tariffs could still be levied against imported drugs and vaccines.”

Similarly, analysts at Bryan Garnier Research pointed out that Trump’s mixed messaging left room for potential future tariff risks.

The US president had remarked that drugmakers “will come roaring back to the US, because if they don’t, they got a big tax to pay.”

Asian, Indian healthcare stocks rally

Asian healthcare stocks also rallied, led by Indian generic drugmakers, even as the broader market declined.

The CNX Pharma index, which tracks Indian pharmaceutical companies, surged more than 3%, marking its biggest one-day gain in 10 months.

In contrast, India’s benchmark Nifty 50 index fell 0.25% on the day.

Sun Pharma, Cipla, and Dr. Reddy’s Laboratories, the country’s three largest drugmakers by revenue, gained between 3% and 6%.

India, one of the largest suppliers of generic medicines to the US, stands to benefit the most from the exemption.

The US accounted for nearly a third, or $9 billion, of India’s total pharmaceutical exports last fiscal year, with most of these being low-cost generic drugs.

Japan’s pharmaceutical sector also benefited, with Takeda Pharmaceuticals and Daiichi Sankyo advancing 2% and 2.7%, respectively.

However, Japan’s broader Nikkei 225 index tumbled to an eight-month low, reflecting investor concerns over the wider impact of US tariffs on global trade.

Japan’s exports to the US were also substantial, amounting to $6.34 billion in 2023, according to data from research firm OEC.

Jefferies analysts noted that while Indian drugmakers “can breathe easy for now,” the risk of future tariffs remains.

“Higher tariffs at a later date cannot be ruled out, but for now, this exemption allows Indian firms to maintain their competitive edge in the US market,” Jefferies said in a note.

What to expect in the coming days?

Looking ahead, analysts suggest that pharmaceutical companies will closely monitor the Trump administration’s stance on trade policies.

Bloomberg has reported that the US government is considering launching a Section 232 investigation into pharmaceuticals, semiconductors, and critical minerals, similar to previous probes that resulted in tariffs on cars and aluminium.

BNP Paribas India analyst Tausif Shaikh stated, “Assuming a 10% tariff is imposed on pharma products, we expect the impact to be negligible. However, with the sector exempted from reciprocal tariffs currently, we expect a relief rally for the Nifty Pharma Index, after its 11% year-to-date decline.”

While the immediate outlook for pharmaceutical stocks appears positive, the industry remains vulnerable to policy shifts in the ongoing US trade war.

Investors and drugmakers alike will be watching closely for any further developments from Washington.

The post European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Short US30: bearish momentum strengthens as trade war fears and technical breakdown signal further downside risk
next post
Is it a golden opportunity to buy the Nasdaq 100 index crash?

Related Posts

Here’s why the Nio stock price dropped in...

May 26, 2025

Falcon Finance enhances asset security with Fireblocks Off...

March 7, 2025

Why Boeing delays could benefit Ryanair shareholders

November 5, 2024

JPMorgan CEO Jamie Dimon hopes for soft landing...

May 1, 2024

McDonald’s $5 value meal is coming in June...

May 18, 2024

US widens AI export bans to 80 firms,...

March 26, 2025

S&P 500 slips from intraday highs as investors...

January 25, 2025

Brazil’s B3 reports7% revenue growth in Q4 despite macroeconomic...

February 22, 2025

Val Kilmer dies at 65 in Los Angeles,...

April 2, 2025

Vedanta share price forms a risky pattern as...

September 18, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Interview: Strategic location gives Brazil Potash cost advantage in domestic fertiliser market, says CEO Matt Simpson

      June 1, 2025
    • Canada’s Q1 GDP expands by 2.2%, driven by exports spike ahead of potential US tariffs

      June 1, 2025
    • President Trump to host farewell for Elon Musk as DOGE leader steps away

      June 1, 2025
    • UK’s digital banks face divergent fortunes: Starling stumbles, Monzo and Revolut soars

      June 1, 2025
    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025

    Categories

    • Business (3,022)
    • Investing (2,459)
    • Latest News (1,994)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved